Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Head and Neck Cancer, Squamous Cell Cancer

In brief

The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer

Key facts

Study ID

NCT00401401

Run by

Genmab

People needed

30

Starts

2006-12-01

Expected to finish

2010-10-01

Last updated by the study team

2011-12-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx

You may not qualify if…

• Prior treatment with radiotherapy in the head and neck area
• Prior treatment with chemotherapy
• Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors)
• Previous surgery with curative intent for head and neck cancer

Where it is running

• Oregon Health Sciences Center — Portland, Oregon, United States
• St-Luc University Hospital — Brussels, Belgium
• University Hospital Gasthuisberg — Leuven, Belgium
• Centre Georges-Francois Leclerc Hospital — Dijon, France
• Hopital Bretonneau Clinique d'Oncologie et Radiothérapie — Tours, France
• Nijmegen University Hospital — Nijmegen, Netherlands
• Lund University Hospital — Lund, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.